Scarica l'app Stockscreener
155.87
0.56%
0.87
Dopo l'orario di chiusura:
156.50
0.63
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GH Giù?
Forum
Previsione
Precedente Chiudi:
$155.00
Aprire:
$152.73
Volume 24 ore:
2.00M
Relative Volume:
0.76
Capitalizzazione di mercato:
$20.67B
Reddito:
$1.08B
Utile/perdita netta:
$-433.19M
Rapporto P/E:
-45.84
EPS:
-3.4004
Flusso di cassa netto:
$-225.09M
1 W Prestazione:
-2.61%
1M Prestazione:
+20.73%
6M Prestazione:
+39.00%
1 anno Prestazione:
+229.67%
Intervallo 1D:
$149.78
$157.33
Intervallo di 1 settimana:
$149.78
$164.98
Portata 52W:
$40.35
$174.08
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
155.87 | 20.55B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
532.48 | 201.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
203.83 | 145.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.44 | 45.44B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
271.39 | 38.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.46 | 38.44B | 7.23B | 1.41B | 1.09B | 4.979 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
GH Maintains Rating by Guggenheim -- Price Target Raised to $190 - GuruFocus
Form 144 Guardant Health For: 16 July By Investing.com - Investing.com Canada
Guardant Health director Tariq Musa sells $18,941 in stock - Investing.com
Form 4 Guardant Health Inc For: 16 July By Investing.com - Investing.com Canada
Guardant Health director Tariq Musa sells $18,941 in stock By Investing.com - Investing.com UK
Musa Tariq plans sale of Guardant Health (NASDAQ: GH) common stock - Stock Titan
Canadian AI Microcap Cut Hospital Drug Alerts by 94%. Now It’s Entering the U.S. (TSXV: SEGN) - Benzinga
Guggenheim raises Guardant Health stock price target on Shield data - Investing.com
Guggenheim raises Guardant Health stock price target on Shield data By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
TD Cowen raises Guardant Health stock price target on FDA approval - Investing.com
How Expanded Coverage for Guardant’s Shield Test Will Impact UnitedHealth Group (UNH) Investors - simplywall.st
GH Maintained by Canaccord Genuity -- Price Target Raised to $20 - GuruFocus
Guardant Health (GH) Receives a Buy from Bank of America Securities - The Globe and Mail
BofA Securities Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $190 - Moomoo
Will Expanded Coverage of Guardant’s Shield Test Reshape UnitedHealth Group’s (UNH) Preventive Care Narrative? - Yahoo Finance
Goldman Sachs Maintains Guardant Health(GH.US) With Buy Rating, Maintains Target Price $165 - Moomoo
What Drove Guardant Health's Q4 2025 Performance and 2026 Outlook - Kavout | AI
Press Release: Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026 - Moomoo
Cancer Blood Screen Company’s SPAC Merger Is Delayed by Test’s Results - Barron's
Guardant Health sets July 30 call for Q2 2026 results - Stock Titan
Guardant Health (GH) Stock May Be Fully Priced As Shield Coverage Expands - simplywall.st
GH Maintained by Morgan Stanley -- Price Target Raised to $175 - GuruFocus
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $161.13, Implies 3% Upside - TradingView
Morgan Stanley Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $175 - Moomoo
Guardant Health Slides as Investors Appear to Take Profits After Recent Rally - Moomoo
Citi Maintains Guardant Health(GH.US) With Buy Rating, Raises Target Price to $215 - Moomoo
FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint - AOL.com
American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines - AOL.com
Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting - AOL.com
Responsive Playbooks and the GH Inflection - Stock Traders Daily
ETFs Investing in Guardant Health, Inc. Stocks - TradingView
GH Maintained by Evercore ISI Group -- Price Target Raised to $2 - GuruFocus
Guardant Health, Inc. Stock 12‑Month Price Target Raised to $156.35, Implies 7% Downside - TradingView
Guardant Health stock hits 52-week high at $172.67 By Investing.com - Investing.com South Africa
Guardant Health stock hits 52-week high at $172.67 - Investing.com
Guardant Health: Great Execution, But At An Excessive Premium (NASDAQ:GH) - Seeking Alpha
Guardant Health Is Maintained at Buy by B of A Securities - Moomoo
BofA raises Guardant Health stock price target on FDA wins By Investing.com - Investing.com Canada
Zydus and Apollo Hospitals sign MoU to launch MCD test in India - Yahoo Finance
Guardant Health Q1 2026 slides: revenue soars 48% on Shield momentum - Investing.com
Guardant Health stock surges on colon cancer blood test news - Yahoo Finance
Guardant Health earnings on deck as cancer test volumes surge - Investing.com
GHGuardant Health Inc Latest SEC Filings - Finviz
Guardant Health (GH) Stock May Look Fully Valued Following Shield Coverage News - Yahoo Finance
Zydus, Guardant Health and Apollo Hospitals partner to launch multi-cancer blood test in India - Indian Pharma Post
Why Guardant Health (GH) Is Up 12.6% After Joining the Russell 1000 and Major Indexes – And What's Next - Yahoo Finance
Form 4 Guardant Health Inc For: 2 July By Investing.com - Investing.com Canada
Guardant Health (GH) CLO exercises RSUs as shares withheld for taxes - Stock Titan
Guardant Health | 4: Statement of changes in beneficial ownership of securities-Officer Saia John G. - Moomoo
Guardant Health (GH) CPO logs RSU vesting and $170.77 tax-withholding share transfer - Stock Titan
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.61%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):